FDA Pipeline preview, October 2008 (vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, imatinib)

Recent FDA action (through October 2008) related to vernakalant, doripenem, custirsen, droxidopa, amrubicin, dronedarone, and imatinib.

Approvable designation*

Complete responses*

Fast-track designations

Orphan drug designations